(Reuters) -Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker’s strategy to diversify beyond its blockbuster cancer treatment Keytruda.
The move adds to a growing list of high-profile transactions over the past decade by U.S. pharmaceutical companies to acquire promising therapies in fields ranging from oncology, neurology to rare diseases and obesity.
Globally, $105.3 billion worth of pharmaceuticals and biotech M&A deals have been inked so far in 2025, according to data compiled by LSEG, up 7% from year-ago levels and the highest year-to-date total since 2023.
Below are some of the major deals involving U.S.-based pharma and biotech firms from the past decade
Year Acquirer Target Deal Value Description
2025 Merck & Co Verona About $10 Strengthens
Pharma billion Merck’s
respiratory
portfolio amid
looming
Keytruda
patent cliff
2025 Johnson & Intra-Cell $14.6 Expands J&J’s
Johnson ular billion footprint in
Therapies brain disease
treatments
2024 Novo Catalent $16.5 Boosts
Holdings billion manufacturing
(including capacity for
debt), Novo Nordisk’s
$11.5 popular
billion obesity drug
(excluding Wegovy
debt)
2023 Merck & Co Prometheus $10.8 Adds
Bioscience billion experimental
s treatment for
ulcerative
colitis and
Crohn’s
disease and
builds up
presence in
immunology
2023 Bristol Karuna BMY gains a
Myers Therapeuti $14 promising
Squibb cs billion antipsychotic
medicine as
patents on its
older
therapies near
their expiry
2023 Pfizer Seagen $43 Builds
billion Pfizer’s
cancer
portfolio amid
decline in
sales for
COVID-related
products and
generic
competition
2022 Amgen Horizon $27.8 Buyout,
Therapeuti billion biggest in the
cs sector in
2022,
fortifies rare
diseases
portfolio
2022 Pfizer Biohaven $11.6 Pfizer bets
Pharmaceut billion big on a new
ical class of
Holding migraine drugs
2021 Merck & Co Acceleron About Diversifies
Pharma $11.5 Merck’s
billion portfolio
beyond cancer
2021 Ginkgo Soaring $17.5 Ginkgo said it
Bioworks Eagle million plans to go
Acquisitio public through
n a merger with
a blank-check
vehicle backed
by former
Hollywood
executives
Harry Sloan
and Jeff
Sagansky
2020 AstraZeneca Alexion $39 AstraZeneca’s
Pharmaceut billion largest ever
icals deal to
diversify away
from its
cancer
business,
betting on
rare-disease
and immunology
drugs
2020 Bristol MyoKardia About $13 Bolster
Myers billion Bristol’s
Squibb portfolio of
heart disease
treatments
2020 Gilead Immunomedi $21 Strengthens
cs billion Gilead’s
cancer
portfolio
2019 Mylan Pfizer’s About $12 Mylan’s
Upjohn billion acquisition of
business Pfizer’s
